Rigel Pharmaceuticals, Inc. (RIGL) Analysts See $-0.15 EPS; 7 Bullish Analysts Covering Tsakos Energy Navigation Ltd. (TNP)

October 13, 2017 - By Nellie Frank

Analysts expect Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report $-0.15 EPS on November, 7.They anticipate $0.09 EPS change or 37.50% from last quarter’s $-0.24 EPS. After having $-0.16 EPS previously, Rigel Pharmaceuticals, Inc.’s analysts see -6.25% EPS growth. The stock decreased 1.82% or $0.07 during the last trading session, reaching $3.77. About 3.87 million shares traded or 69.00% up from the average. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has risen 4.56% since October 13, 2016 and is uptrending. It has underperformed by 12.14% the S&P500.

Among 10 analysts covering Tsakos Energy Navigation Ltd (NYSE:TNP), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Tsakos Energy Navigation Ltd had 20 analyst reports since January 19, 2016 according to SRatingsIntel. Credit Suisse downgraded the stock to “Neutral” rating in Friday, January 13 report. The company was maintained on Friday, September 15 by Cowen & Co. The company was reinitiated on Wednesday, May 4 by Seaport Global. Jefferies maintained the shares of TNP in report on Wednesday, July 27 with “Buy” rating. The rating was maintained by Maxim Group with “Buy” on Monday, April 24. The stock of Tsakos Energy Navigation Ltd. (NYSE:TNP) earned “Buy” rating by Jefferies on Tuesday, May 30. The stock of Tsakos Energy Navigation Ltd. (NYSE:TNP) has “Hold” rating given on Wednesday, August 2 by Wells Fargo. As per Tuesday, March 15, the company rating was maintained by JP Morgan. The stock has “Buy” rating by Stifel Nicolaus on Friday, September 15. The rating was maintained by Jefferies on Monday, July 3 with “Buy”. See Tsakos Energy Navigation Ltd. (NYSE:TNP) latest ratings:

18/09/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $6 New Target: $5.5 Maintain
15/09/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $7.0 Maintain
15/09/2017 Broker: Cowen & Co Rating: Buy Old Target: $7.00 New Target: $6.00 Maintain
12/09/2017 Broker: Maxim Group Rating: Buy New Target: $7.0
11/09/2017 Broker: Jefferies Rating: Buy New Target: $6.0 Maintain
07/08/2017 Broker: Jefferies Rating: Buy New Target: $6.0000 Maintain
02/08/2017 Broker: Wells Fargo Rating: Hold New Target: $3.2500 Downgrade
07/07/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $9.0000 Maintain
03/07/2017 Broker: Jefferies Rating: Buy New Target: $6.0000 Maintain
30/05/2017 Broker: Jefferies Rating: Buy New Target: $6.0000 Maintain

The stock increased 2.36% or $0.11 on October 13, reaching $4.55. About 152,150 shares traded. Tsakos Energy Navigation Ltd. (NYSE:TNP) has declined 21.03% since October 13, 2016 and is downtrending. It has underperformed by 37.73% the S&P500.

Tsakos Energy Navigation Ltd is a provider of international seaborne crude oil and petroleum product transportation services. The company has market cap of $383.89 million. The Firm operates through maritime transportation of liquid energy related products segment. It has a 23.02 P/E ratio. It operates a fleet of approximately 57 modern crude oil and petroleum product tankers that provide marine transportation services for national and other independent oil companies and refiners under long, medium and short-term charters.

Investors sentiment increased to 1.59 in Q2 2017. Its up 0.37, from 1.22 in 2017Q1. It improved, as 4 investors sold Rigel Pharmaceuticals, Inc. shares while 28 reduced holdings. 16 funds opened positions while 35 raised stakes. 105.05 million shares or 0.54% more from 104.49 million shares in 2017Q1 were reported. Parametric Portfolio Ltd Co has 30,083 shares. Next Grp Inc Inc stated it has 1,950 shares. State Street has invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Franklin Street Advsrs Incorporated Nc reported 20,000 shares. Sg Americas Secs Lc accumulated 11,529 shares. Macquarie Gp Limited stated it has 0% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Legal & General Gp Pcl reported 30,605 shares. Comml Bank Of Ny Mellon accumulated 555,517 shares or 0% of the stock. Prelude Ltd reported 9,691 shares. The Maryland-based Nea Limited Liability Corporation has invested 0.32% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Moreover, Axa has 0% invested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Alliancebernstein L P owns 144,740 shares or 0% of their US portfolio. Moreover, Nationwide Fund Advisors has 0% invested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) for 247,659 shares. Metropolitan Life Commerce New York stated it has 93,287 shares or 0% of all its holdings. Jacobs Levy Equity Mngmt holds 0% or 80,600 shares.

Among 4 analysts covering Rigel Pharmaceuticals (NASDAQ:RIGL), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rigel Pharmaceuticals had 11 analyst reports since August 8, 2015 according to SRatingsIntel. Piper Jaffray maintained the stock with “Overweight” rating in Tuesday, August 30 report. The rating was maintained by Jefferies with “Buy” on Monday, September 4. Jefferies maintained the shares of RIGL in report on Monday, May 16 with “Buy” rating. The stock has “Buy” rating by BMO Capital Markets on Monday, June 19. As per Wednesday, July 13, the company rating was initiated by H.C. Wainwright. The company was maintained on Monday, October 2 by BMO Capital Markets. Piper Jaffray initiated the shares of RIGL in report on Monday, June 13 with “Overweight” rating. The stock has “Outperform” rating by BMO Capital Markets on Wednesday, August 31. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, August 31. As per Wednesday, June 7, the company rating was maintained by BMO Capital Markets.

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The company has market cap of $535.11 million. The Firm is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. It currently has negative earnings. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com